Roche has developed a specific patent policy for its HIV antiretroviral medicines, which commits that:
- In addition to not filing or enforcing patents on any Roche medicines in the Least Developed Countries*, Roche will not file patents on new antiretrovirals (ARVs) in sub-Saharan Africa, the poorest and hardest hit region
- Roche will not take any action against generic manufacturers of its ARVs Invirase and Viracept in these countries
Roche provides letters granting immunity from suit, upon request, to generic manufacturers interested in producing generic versions of its antiretroviral medicines for Least
Developed Countries and sub-Saharan Africa. This policy enables local manufacturers to produce generic antiretroviral medicines for supply to sub-Saharan Africa and the Least Developed Countries without prior consent. To help strengthen the manufacturing capability and capacity within these countries, Roche also launched a new initiative in January 2006 – the AIDS Technology Transfer Initiative – to provide local manufacturers with the technical expertise to produce their own generic version of saquinavir.
Removing Barriers, Increasing Access PDF